title: Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases.
abstract: Activation of the p53 tumour suppressor protein by distinct forms of stress leads to inhibition of cellular proliferation by inducing cell cycle arrest or apoptosis. The cyclin-dependent kinase inhibitor roscovitine has been shown to induce nuclear accumulation of wild-type p53 in human untransformed and tumour-derived cells. We analyzed the response of different human tumour cell lines to roscovitine treatment with respect to their p53 status. Striking induction of wild-type p53 protein and dramatic enhancement of p53-dependent transcription, coinciding with p21WAF1 induction, was observed in wildtype, but not mutant, p53-bearing tumour cells after treatment with roscovitine. The transcriptional activity of p53 was substantially higher in roscovitine-treated cells than in cells irradiated with ultraviolet C or ionizing radiation, even though all these agents induced a similar amount of p53 accumulation. These results highlight the therapeutic potential of roscovitine as an anticancer drug, especially in tumours retaining a functional wild-type p53 pathway.
authors.affiliation: Department of Experimental Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: V
authors.initials: V
authors.lastname: Kotala
authors.forename: S
authors.initials: S
authors.lastname: Uldrijan
authors.forename: M
authors.initials: M
authors.lastname: Horky
authors.forename: M
authors.initials: M
authors.lastname: Trbusek
authors.forename: M
authors.initials: M
authors.lastname: Strnad
authors.forename: B
authors.initials: B
authors.lastname: Vojtesek
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms; D002460:Cell Line; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000378:metabolism*; D016213:Cyclins / Q000235:genetics / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005347:Fibroblasts; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007700:Kinetics; D008545:Melanoma; D051379:Mice; D012516:Osteosarcoma; D011687:Purines / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000378:metabolism; D000077546:Roscovitine; D014158:Transcription, Genetic; D014162:Transfection; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; C493957:Cdkn1a protein, mouse; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D004791:Enzyme Inhibitors; D011687:Purines; D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53; D000077546:Roscovitine; D018844:Cyclin-Dependent Kinases